Compare · NVO vs PEPG
NVO vs PEPG
Side-by-side comparison of Novo Nordisk A/S (NVO) and PepGen Inc. (PEPG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PEPG operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.64B, about 1910.7x PEPG ($100.3M).
- Over the past year, NVO is down 40.8% and PEPG is down 8.1% - PEPG leads by 32.7 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 10 for PEPG).
- NVO has more recent analyst coverage (25 ratings vs 4 for PEPG).
- Company
- Novo Nordisk A/S
- PepGen Inc.
- Price
- $42.01-2.10%
- $1.42-2.74%
- Market cap
- $191.64B
- $100.3M
- 1M return
- -5.38%
- -20.67%
- 1Y return
- -40.76%
- -8.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 11
- 10
- Recent ratings
- 25
- 4
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Latest PEPG
- Chief Technical Officer Kasraian Kasra sold $1,739 worth of shares (1,233 units at $1.41) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 50,074 units (SEC Form 4) (withholding tax)
- SEC Form EFFECT filed by PepGen Inc.
- PepGen Inc. filed SEC Form 8-K: Regulation FD Disclosure
- PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
- SEC Form S-3 filed by PepGen Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.
- PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by PepGen Inc.
- PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights